Phase 3 Haemophilia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have moderately severe Hemophilia A, meaning your body produces very low levels of a clotting protein called Factor VIII
- You are 6 years old or older at the time of signing up for the trial
- You have been tested on 2 separate occasions and shown to have a high level of "inhibitors" (antibodies that block clotting treatment), with both tests done within the last 2 years
- You or your parent/guardian has agreed to take part and signed a consent form
- Your blood counts (red blood cells and platelets) are at an acceptable level based on a blood test
- Your liver is functioning well enough, based on blood test results (confirm with trial site)
- Your kidneys are functioning well enough, based on blood test results (confirm with trial site)
Who may not be able to join:
- You have another bleeding disorder in addition to Hemophilia A (some exceptions may apply — confirm with trial site)
- You were actively bleeding and needed clotting factor treatment at the time of your screening appointment
- You have had, or currently have, blood clot problems (with some exceptions for previously resolved clots from medical lines)
- You had surgery within 14 days before your screening appointment
- You have a condition that may raise your risk of bleeding or blood clots
- You were treated with certain clotting medications (rFVIIa or aPCC) within 7 days before screening
- You have had a significant allergic reaction to a monoclonal antibody therapy or to any ingredient in the study drug (emicizumab)
- You are currently taking any other medication (besides emicizumab) that could affect how your blood clots
- You have HIV with a low immune cell count (below 200 CD4 cells), if you are 35 years of age or older
- You are currently taking, or plan to take, medications that affect your immune system during the study
- You are considered at high risk for a condition called TMA (a serious condition affecting blood and organs — confirm with trial site)
- You have another illness, treatment, or abnormal test result that the trial doctor believes could make it unsafe for you to participate
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Robert Sidonio, MD, Emory University
Phone: 404-785-1637
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Thrombin generation capacity after aPCC (FEIBA) infusion
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.